Pharma powerhouse Séamus Mulligan pumps €5.35 million into cell engineering firm

Mulligan, whose pharma firm Adapt was sold for $635 million in 2018, first invested in Maynooth-based Avectus in 2014

Adapt’s 2018 sale followed the development of its Narcan nasal spray, fast-tracked by the US drug regulator in the face of the country’s opioid crisis.